Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quinupramine
- Development stage
- Unknown
- Lead developer
- Bellon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quinupramine is a tricyclic antidepressant (TCA) that has been approved in France and some other European countries for the treatment of depression. It is structurally related to other TCAs but features a unique bicyclic side chain (quinuclidine moiety). Like other TCAs, its mechanism of action involves inhibition of the reuptake of norepinephrine and serotonin, increasing their levels in the synaptic cleft and thereby enhancing neurotransmission. This pharmacological activity underlies its antidepressant effects. Quinupramine may also interact with muscarinic acetylcholine receptors, histamine H1 receptors, and alpha1 adrenergic receptors, contributing to its side effect profile[6][8][10].
- Brand names
- KinuprilKevoprilAdeprimQuinuprine
- Other names
- quinupraminequinupraminaquinupraminum10,11-dihydro-5-(3-quinuclidinyl)-5H-dibenz[b,f]azepine
02
Targets
SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on quinupramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quinupramine.